DexCom, Inc.
DXCMHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, DexCom, Inc. focuses on Medical Devices services and products. DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in. With a market capitalization of $31.90B, it sits in large-cap territory. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.
Market Cap
$31.90B
Beta
1.42
P/E (TTM)
33.41
P/E (Fwd)
27.06
EPS (TTM)
$2.53
EPS (Fwd)
$3.12
ROE
38.5%
ROA
10.3%
Cash
$1.95B
Total Debt
$1.40B
Free CF
$1.02B
52W Change
15.7%
Annual Financials
Cash vs Debt
Where DXCM stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, DXCM finished 24.99% above its 150-day moving average ($71.44) and 27.65% above its 200-day moving average ($69.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DXCM overbought or oversold?
At the August 28, 2026 close, DXCM's RSI(14) was 63.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.95B in cash comfortably exceeding the $1.40B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $1.02B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 38.5%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.3% further supports the picture of efficient asset utilization. Revenue has grown from $2.91B (2022) to $4.66B (2025), reflecting a 60% increase over the period.
Investors considering DexCom, Inc. should weigh the typical risks associated with DXCM's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence DexCom, Inc.'s trajectory.